Overcoming barriers to first injectable therapies in type 2 diabetes
Dr Tom Dover (Endocrinologist, Queensland Health) and Dr Ashraf Saleh (GP, Toowomba, Qld) discuss the role of injectable therapies in the ongoing management of type 2 diabetes, and outline methods to reduce barriers and improve patient outcomes.
Note: The ‘Stop rule’ mentioned in this video has been changed to the ‘Review rule’ in the 2020 RACGP handbook.
Questions asked in the video
- How can we deliver effective ongoing management for people with type 2 diabetes? 0:00
- How can we overcome some key barriers to initiating injectable therapy? 1:34
- Which agent is recommended for type 2 diabetes patients initiating injectable therapy? 2:33
- How would you manage a patient experiencing gastrointestinal issues on a GLP-1 RA? 3:35
- How can we tailor our communication to patients who may have poor health literacy? 5:58
For further information and CPD education about first injectable therapies for type 2 diabetes, enrol in our Rethinking first injectable therapies in type 2 diabetes: A practical approach ALM.
This activity is sponsored by Eli Lilly Australia.
The views and statements contained within may not reflect those of the sponsor.